Acceleron Pharma Inc (XLRN) Stock
XLRN is no longer traded. Acceleron Pharma was acquired by Merck (MRK) on November 22, 2021.
Each XLRN share was exchanged for $180.00 in cash. Prices on this page are historical; the last trade was November 19, 2021 at $178.75.
See Merck (MRK) stock →Acceleron Pharma stock price history
XLRN final trading statistics
- Final close
- $178.75
- Final trading day
- Nov 19, 2021
- Market cap at delisting
- $10.93B
- Shares outstanding
- 61.16M
- Final 52-week range
- $108.82 – $189.99
- Avg. volume (final 3 mo.)
- 1,293,535
- All-time high (split-adj.)
- $182.78 · Sep 2021
- All-time low (split-adj.)
- $17.40 · Nov 2013
- Return since IPO
- +794.2%
- Beta
- 0.13
- Book value / share
- $11.75
- Price / book
- 15.22
Acceleron Pharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2020 | $92.52M | -$166.0M | -$2.90 |
| FY2019 | $73.99M | -$124.9M | -$2.38 |
| FY2018 | $13.99M | -$118.9M | -$2.59 |
| FY2017 | $13.48M | -$108.5M | -$2.70 |
| FY2016 | $27.77M | -$57.0M | -$1.52 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Acceleron Pharma Inc
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. As of November 19, 2021, Acceleron Pharma Inc. operates as a subsidiary of Merck Sharp & Dohme Corp.
Acceleron Pharma stock FAQ
What happened to Acceleron Pharma stock?
Acceleron Pharma was acquired by Merck (MRK) on November 22, 2021. Shareholders received $180.00 in cash for each share. XLRN stock stopped trading on the Nasdaq, with a final close of $178.75 on November 19, 2021.
What did Acceleron Pharma shareholders receive?
Each XLRN share was converted into $180.00 in cash. The deal was valued at about $11.5 billion.
Is XLRN stock still trading?
No. XLRN was delisted from the Nasdaq on November 22, 2021 and no longer trades on a U.S. exchange.
What was the last price of XLRN stock?
XLRN closed at $178.75 on its final trading day, November 19, 2021, for a market value of about $10.93B.
What were Acceleron Pharma's revenue and earnings in its last full fiscal year?
Acceleron Pharma reported revenue of $92.52M and net income of -$166.0M in fiscal 2020, its last full year as a public company.
When did Acceleron Pharma go public?
Acceleron Pharma Inc stock began trading on September 19, 2013.